Table 20:
Volume After Accounting for Uptake of Multi-gene Pharmacogenomic Testing in Ontario During Years 1 to 5
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| No. of eligible people with major depression | 183,547 | 186,51 | 189,263 | 191,791 | 194,106 |
| Uptake rate | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 |
| No. of people who continue TAU | 181,711 | 182,818 | 183,696 | 184,342 | 184,773 |
| No. of people to be assessed with multi-gene pharmacogenomic testinga | 1,835 | 3,694 | 5,512 | 7,230 | 8,792 |
Abbreviation: TAU, treatment as usual.
a
Uptake rate applied to approximate total of remaining people eligible for testing in specific year, reference case analysis: e.g., year 1: 183,547 × 0.01 = 1,835; year 2: (186,512 – 1,835) × 0.02 = 3,694. Those tested in prior years are subtracted from population in following years, as cost of test is applied only once over a person's lifetime.99